HK1201452A1 - Methods of reducing risk of cardiovascular disease - Google Patents
Methods of reducing risk of cardiovascular disease Download PDFInfo
- Publication number
- HK1201452A1 HK1201452A1 HK15101958.1A HK15101958A HK1201452A1 HK 1201452 A1 HK1201452 A1 HK 1201452A1 HK 15101958 A HK15101958 A HK 15101958A HK 1201452 A1 HK1201452 A1 HK 1201452A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- patient
- ldl
- compound
- formula
- risk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584002P | 2012-01-06 | 2012-01-06 | |
| US61/584,002 | 2012-01-06 | ||
| PCT/US2013/020317 WO2013103842A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19131240.4A Addition HK40007806A (en) | 2012-01-06 | 2015-02-27 | Methods of reducing risk of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201452A1 true HK1201452A1 (en) | 2015-09-04 |
Family
ID=48745439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101958.1A HK1201452A1 (en) | 2012-01-06 | 2013-01-04 | Methods of reducing risk of cardiovascular disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10028926B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3735967A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6295205B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110025608A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013207423B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2861643C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1201452A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX367352B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013103842A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| US9440754B2 (en) | 2012-03-29 | 2016-09-13 | R.P. Scherer Technologies, Llc | Three circuit fill system for blow fill seal containers |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| CN107530307A (zh) | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| SG10201912754UA (en) * | 2015-11-06 | 2020-02-27 | Gemphire Therapeutics Inc | Treatment of mixed dyslipidemia |
| MX2018010096A (es) * | 2016-02-26 | 2018-11-09 | Gemphire Therapeutics Inc | Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos. |
| EP4461295A3 (en) * | 2017-02-08 | 2025-01-15 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease |
| CA3059073A1 (en) * | 2017-04-18 | 2018-10-25 | Daniela Carmen Oniciu | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| TW201906599A (zh) * | 2017-05-11 | 2019-02-16 | 美商珍費爾醫療公司 | 吉卡賓組成物及其使用方法 |
| CN109666727B (zh) * | 2018-12-29 | 2020-11-06 | 中国药科大学 | 一种高活性抑制pcsk9表达的微小rna的用途 |
| MX2021015935A (es) | 2019-06-21 | 2022-04-26 | Esperion Therapeutics Inc | Formas de sal de acido bempedoico y metodos para utilizar el mismo. |
| CN113134086B (zh) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US20020103252A1 (en) | 1997-12-12 | 2002-08-01 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| DE60037818D1 (de) | 1999-04-01 | 2008-03-06 | Esperion Therapeutics Inc | Ether-verbindungen, zusammensetzungen und ihre verwendung |
| JP2004529069A (ja) | 2000-10-11 | 2004-09-24 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用 |
| US6645170B2 (en) | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
| US7579504B2 (en) | 2005-12-07 | 2009-08-25 | Gilead Sciences, Inc. | ABCA1 elevating compounds |
| JP5270545B2 (ja) | 2006-08-03 | 2013-08-21 | タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ | フラッシングのないナイアシン類似体およびそれらの使用法 |
-
2013
- 2013-01-04 CA CA2861643A patent/CA2861643C/en active Active
- 2013-01-04 CN CN201910123564.7A patent/CN110025608A/zh active Pending
- 2013-01-04 US US14/370,722 patent/US10028926B2/en not_active Expired - Fee Related
- 2013-01-04 CN CN201380004642.2A patent/CN104136023A/zh active Pending
- 2013-01-04 AU AU2013207423A patent/AU2013207423B2/en not_active Ceased
- 2013-01-04 WO PCT/US2013/020317 patent/WO2013103842A1/en not_active Ceased
- 2013-01-04 JP JP2014551345A patent/JP6295205B2/ja active Active
- 2013-01-04 MX MX2014008180A patent/MX367352B/es active IP Right Grant
- 2013-01-04 EP EP20166700.3A patent/EP3735967A1/en not_active Withdrawn
- 2013-01-04 EP EP13733913.1A patent/EP2800564B1/en active Active
- 2013-01-04 HK HK15101958.1A patent/HK1201452A1/xx unknown
-
2018
- 2018-02-19 JP JP2018026939A patent/JP2018104452A/ja active Pending
- 2018-06-29 US US16/024,288 patent/US10709678B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150005386A1 (en) | 2015-01-01 |
| AU2013207423A1 (en) | 2014-07-24 |
| US20180303779A1 (en) | 2018-10-25 |
| JP2015503588A (ja) | 2015-02-02 |
| EP2800564B1 (en) | 2020-05-06 |
| CA2861643A1 (en) | 2013-07-11 |
| AU2013207423B2 (en) | 2017-10-12 |
| US10709678B2 (en) | 2020-07-14 |
| JP6295205B2 (ja) | 2018-03-14 |
| CA2861643C (en) | 2020-10-06 |
| EP2800564A1 (en) | 2014-11-12 |
| CN104136023A (zh) | 2014-11-05 |
| MX367352B (es) | 2019-08-16 |
| CN110025608A (zh) | 2019-07-19 |
| US10028926B2 (en) | 2018-07-24 |
| WO2013103842A1 (en) | 2013-07-11 |
| JP2018104452A (ja) | 2018-07-05 |
| EP2800564A4 (en) | 2015-07-22 |
| EP3735967A1 (en) | 2020-11-11 |
| MX2014008180A (es) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10709678B2 (en) | Methods of reducing risk of cardiovascular disease | |
| Nikolic et al. | ETC-1002: a future option for lipid disorders? | |
| US11744816B2 (en) | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
| WO2013136277A1 (en) | Pharmaceutical compositions for treatment of cardiovascular diseases | |
| WO2019178023A1 (en) | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | |
| JP2009540003A (ja) | Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善 | |
| HK1250484A1 (zh) | 用於治疗胰腺炎的吉卡宾和衍生物 | |
| HK40007806A (en) | Methods of reducing risk of cardiovascular disease | |
| WO2020046836A1 (en) | Combination drug formulations for treating patients with cardiovascular disease and associated conditions | |
| AU2015202580B2 (en) | Gemcabene and derivatives for treating pancreatitis | |
| CN102416015A (zh) | 一种含他汀类药物的组合物及其用途 | |
| HK1238159A1 (en) | Gemcaben for treating pancreatitis | |
| HK1192147A (en) | Gemcabene and derivatives for treating pancreatitis | |
| MXPA05003599A (en) | Simvastatin combinations for improving the lipid profile and reducing risk factors of cardiovascular diseases in patients with dyslipidemic disorders | |
| JP2013032400A (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物２ |